In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (09/2011)

Executive Summary

This Month's Profile Group: Cartilage Repair: Opportunities In Motion-Preserving Orthopedics, features profiles of Articulinx, Carticept Medical and Orthox. Plus these Start-Ups Across Health Care: Ellipse Technologies, JDP Therapeutics, NuMe Health and SironRX Therapeutics.

You may also be interested in...



NuMe Health Inc.

NuMe Health Inc. aims to market mixtures of edible substances that will act as "prebiotics" to shift ratios of certain bacteria in the lower intestine. The start-up intends to educate consumers about how "managing the microbiome" with products that are not drugs can positively affect metabolic health. First up: a mixture NuMe expects will improve biomarkers associated with pre-diabetes.

Orthox Ltd.

UK-based Orthox Ltd. has developed a meniscus replacement technology derived from the high-strength silk proteins found in spider web. The company is hoping to offer the best long-term, load-bearing solution for this underserved segment of the orthopedics market.

JDP Therapeutics Inc.

JDP Therapeutics Inc. is working to reformulate an off-patent oral drug into an injectable form that will treat the peripheral, non-life-threatening symptoms of acute allergic reactions to substances such as peanuts and seafood. The benefit envisioned? Fewer side effects than the IV Benadryl currently given to relieve body swelling and itching.

Related Content

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel